Trevi Therapeutics TRVI
NASDAQ TRVI
$14.91 -0.40 (-2.61%)
At close: Nov 10, 2026 · 4:00 PM EST

Trevi Therapeutics (TRVI) Capital Leases (2023)

Updated

Trevi Therapeutics (TRVI) reported Capital Leases of $31,000 for Q4 2023, down 50.0% from the prior quarter.

Analysis

Trevi Therapeutics (TRVI) Capital Leases (2023) Analysis & Trends

Dating back to Q1 2023, Trevi Therapeutics' Capital Leases record includes 4 quarters.

  • Per Business Quant data, the three quarters before Q4 2023 came in at $62,000 (Q3 2023), $93,000 (Q2 2023) and $124,000 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Trevi Therapeutics 2.31 Bn 1.43 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 31,000.00
Sep 30, 2023 62,000.00
Jun 30, 2023 93,000.00
Mar 31, 2023 124,000.00
API Access

Trevi Therapeutics Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=TRVI&period=max&api_key=YOUR_API_KEY